URGN Stock Summary and Trading Ideas (Urogen Pharma Ltd. - | NASDAQ:URGN)

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Urogen Pharma Ltd. - trades on the NASDAQ stock market under the symbol URGN.

As of February 12, 2026, URGN stock price declined to $20.21 with 334,520 million shares trading.

URGN has a beta of 0.56, meaning it tends to be less sensitive to market movements. URGN has a correlation of 0.01 to the broad based SPY ETF.

URGN has a market cap of $946.01 million. This is considered a Small Cap stock.

Last quarter Urogen Pharma Ltd. - reported $28 million in Revenue and -$.69 earnings per share. This fell short of revenue expectation by $-4 million and exceeded earnings estimates by $.01.

In the last 3 years, URGN traded as high as $30.00 and as low as $3.42.

The top ETF exchange traded funds that URGN belongs to (by Net Assets): IWM, IBB, IWO, VTWO, SPDW.

URGN has outperformed the market in the last year with a return of +94.9%, while the SPY ETF gained +14.1%. However, in the most recent history, URGN shares have underperformed the stock market with its stock returning -19.6% in the last 3 month period and -2.3% for the last 2 week period, while SPY has returned 0.0% and -1.8%, respectively.

URGN support price is $20.17 and resistance is $22.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that URGN shares will trade within this expected range on the day.